...
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Thallium-201-chloride scintigraphy in staging and monitoring radiotherapy response in follicular lymphoma patients.
【24h】

Thallium-201-chloride scintigraphy in staging and monitoring radiotherapy response in follicular lymphoma patients.

机译:f 201闪烁闪烁体显像在滤泡性淋巴瘤患者中分期和监测放疗反应。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To study thallium-201-chloride scintigraphy (201Tl-S) in staging and monitoring response after radiotherapy in follicular lymphoma (FL) patients. PATIENTS AND METHODS: Forty-one consecutive and unselected FL patients were examined by 'Conventional Standard Staging' (CSS) procedures (history and physical examination, ultrasound, CT scans, biopsies and fine needle aspiration cytology) prior to irradiation. Eight standardized potentially affected lymphoma localizations (neck, axilla, mediastinum, spleen, paraaortic, parailiac, femoral and extranodal) per patient were separately studied, resulting in the investigation of 328 localizations. Thirty minutes after the intravenous administration of a tracer dose of 150 MBq thallium-201-chloride total body images were made, immediately followed by single photon emission computed tomography acquisition. All lymphoma localizations were subsequently irradiated. Patients were re-examined after a median of 4 weeks (range 3-6 weeks) by all CSS modalities and 201Tl-S. Diagnostic performance was evaluated both per site and per patient, both in the diagnostic phase of the study as well as in the post-treatment re-evaluation phase. RESULTS: In staging, 201Tl-S was positive in 82 of the 129 initial positive regions by CSS (64%). This percentage increased to 70% when eliminating upper abdominal lymph nodes from the analysis. In 24 patients all lesions were visualized by 201Tl-S, in 11 patients some but not all lesions were detected. In six patients none of the lesions were detected by 201Tl-S. In four patients, four additional lesions were initially found by 201Tl-S only. After irradiation, 83 of the total 86 positive regions reached a complete or partial remission by CSS. Eighty-one of these were also diagnosed as remission by 201Tl-S and two as stable disease. In 31 out of 35 patients (89%; 95% CI: 73-97%) the overall response in all irradiated sites was identical by 201Tl-S and CSS. Only two patients, in remission on CSS modalities, showed stable disease on 201Tl-S,while two others were diagnosed as CR by CSS and PR by 201Tl-S. CONCLUSIONS: 201Tl-S has limited additional value in staging FL patients, since only two-thirds of all localizations are detected. However, 201Tl-S is accurate in monitoring radiation treatment response in FL patients. If an FL patient with a positive 201Tl-S at diagnosis is treated by irradiation, the treatment response can be reliably ascertained by only performing a 201Tl-S.
机译:目的:研究滤泡性淋巴瘤(FL)患者放疗后201al氯化物(201T1-S)的显像和监测反应。患者和方法:照射前通过“常规标准分期”(CSS)程序(历史和体格检查,超声,CT扫描,活检和细针穿刺细胞学检查)检查了41例连续且未选出的FL患者。每个患者分别进行了八个标准化的可能受影响的淋巴瘤定位(颈部,腋窝,纵隔,脾,主动脉旁,para侧,股骨和结外)的定位研究,从而对328个定位进行了调查。静脉内施用150 MBqq的201 MBq示踪剂量的全身图像后三十分钟,立即进行单光子发射计算机断层扫描采集。随后对所有淋巴瘤定位进行辐照。在中位数4周(范围3-6周)后,通过所有CSS方式和201T1-S对患者进行了重新检查。在研究的诊断阶段以及治疗后的重新评估阶段,均按部位和按患者评估了诊断性能。结果:在分期中,通过CSS(64%),在129个初始阳性区域中的82个中,201T1-S呈阳性。当从分析中消除上腹部淋巴结时,该百分比增加到70%。在24例患者中,所有病变均通过201T1-S可视化;在11例患者中,发现了一些但不是全部病变。在六名患者中,201T1-S均未检测到病变。在四名患者中,最初仅通过201T1-S发现了另外四个病变。照射后,总共86个阳性区域中的83个通过CSS达到了完全或部分缓解。其中的81例也被201T1-S诊断为缓解,另外2例为稳定疾病。在35名患者中的31名(89%; 95%CI:73-97%)中,所有受照射部位的总体反应与201T1-S和CSS相同。仅有2例因CSS方式缓解而在201T1-S上表现出稳定的疾病,而其他2例被CSS诊断为CR,201T1-S诊断为PR。结论:201T1-S在分期FL患者中具有有限的附加价值,因为仅检测到所有定位的三分之二。然而,201T1-S在监测FL患者中的放射治疗反应方面是准确的。如果通过放射治疗诊断为201T1-S阳性的FL患者,则仅通过进行201T1-S就可以可靠地确定治疗反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号